Navigation Links
ARCALYST® (rilonacept) Meets Primary and All Secondary Endpoints in Second Phase 3 Trial for Prevention of Gout Flares in Patients Initiating Uric Acid-Lowering Therapy
Date:2/28/2011

-related signs and symptoms (7.3% with ARCALYST and 7.3% with placebo), and taking more than the recommended dose (5.6% with ARCALYST and 6.4% with placebo).

About GoutGout is a condition that occurs when the bodily waste product, uric acid, is deposited in the joints and/or soft tissues.  In the joints, these uric acid crystals cause inflammation, which leads to pain, swelling, redness, heat, and stiffness in the joints.  Treatment guidelines recommend that patients with elevated uric acid levels who experience multiple gout attacks each year should receive chronic uric acid-lowering therapy, such as allopurinol.  Allopurinol reduces the production of uric acid in the body to prevent the occurrence of gout attacks with long-term use.  Approximately 750,000 gout patients initiate allopurinol therapy each year.  During the first months of allopurinol therapy while uric acid blood levels are being reduced, the break up of the uric acid crystals can result in stimulation of inflammatory mediators, including interleukin-1 (IL-1), resulting in acute flares of joint pain and inflammation.  Anti-inflammatory therapy with colchicine is sometimes used to help prevent these flares.  However, the side effects associated with colchicine, which include diarrhea, abdominal cramps, nausea, and vomiting, can limit patients' adherence to both colchicine and allopurinol treatment.

Rationale for the Clinical Exploration of Use of ARCALYST® (rilonacept) in the Treatment of GoutInterleukin-1 (IL-1) is a protein secreted by infection-fighting cells in the blood and tissues.  In many cases, IL-1 acts as a messenger to help regulate immune and inflammatory responses by attaching to cell-surface receptors in cells that participate in the body's immune system.  In excess, it can be harmful and has been shown to be a key driver of inflammation in a variety of diseases, including gout.  In gout, uric acid crystals stimu
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
2. New IonWorks Barracuda Automated Patch Clamp System Meets Need for Affordable, Accelerated Screening of Ligand- & Voltage-Gated Ion Channels Via Direct Electrophysiology Assays
3. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
7. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
8. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
9. Jazz Pharmaceuticals and UCB Announce Second Phase III Study of Sodium Oxybate in Patients With Fibromyalgia Meets Primary Endpoints
10. MADIT-CRT Trial Meets Primary Endpoint
11. VIA Pharmaceuticals Meets With FDA to Discuss Next Steps For VIA-2291 and Phase 3 Outcome Trial in Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
(Date:1/22/2015)... , Jan. 22, 2015  ViewRay™, a privately held ... into an exclusive distributor agreement with ITOCHU Corporation (Tokyo ... therapy system for the treatment of cancer in ... system, is the world,s first and only MRI-guided radiation ...
(Date:1/22/2015)... , Jan. 22, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; ... a focus on Omega-3 therapies for cardiovascular disease and overall ... the Company,s accomplishments in 2014 and its outlook for 2015 ... Dear Fellow Shareholders, We would like to take ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... U.S. Food and Drug Administration has scheduled its fourth ... those unfamiliar with the process for Feb. 28 – ... Keck Graduate Institute. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... Organization of Rare Disorders and the Genetic Alliance, will ...
... /PRNewswire-Asia/ -- China Sky One Medical, Inc. ("China ... CSKI ), a leading fully integrated pharmaceutical ... today announced that Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong"), ... a "Top Ten Branded Company Trusted by Consumers" ...
Cached Medicine Technology:Fourth FDA Orphan Drug Designation Workshop Scheduled for Feb. 28 - March 1, 2011 2China Sky One Medical Receives Medical Industry Awards 2China Sky One Medical Receives Medical Industry Awards 3
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue Cross) wants ... “Live Fearless.” , The “Faces of Fearless” campaign ... how they or someone they know has faced a challenge, ... moment. By telling these types of stories through livefearlessmn.com, participants ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
(Date:1/22/2015)... released a new blog post explaining the importance of keeping a ... of an auto insurance policy . , Clients who driver ... their vehicle insurance policies. The safety a vehicle offers from its ... of this, drivers should always carry a first aid kit in ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... Discussions Also to Feature Top Experts on the Battle Against H1N1 ... reform headed to the floor of the House and Senate, the ... discussions designed to shed light on what the looming changes will ... the Top of the Hill Banquet and Conference Center, at the ...
... Company allegedly failed to correct violations , ... of Justice, on behalf of the U.S. Food and ... against Rel,s Foods Inc. (Rel,s), of Oakland, Calif., seeking ... adulterated food products. , (Logo: ...
... Rawat Foundation,s grant to St. John of Jerusalem Eye Hospital will ... 8 A $25,000 grant by The Prem Rawat Foundation (TPRF) ... eye care for 30,000 children in an area of the world ... 50% of the people in the Palestinian Territories, one of the ...
... infection with high-risk types of human papillomavirus (HPV), a ... of cervical cancer. Current guidelines prioritize HPV vaccination of ... in previous studies, but the value of vaccinating boys ... new study, Harvard School of Public Health (HSPH) researchers ...
... Palliative Care Psychiatry Program only one of its kind ... The Palliative Care Psychiatry Program at San ... named the winner of the 2009 Gold Achievement Award by ... Irwin, MD, PhD is Director of the Palliative Care Psychiatry ...
... Reportlinker.com announces that a new market ... , Reportlinker Adds The Market ... Pharmaceutical, Diagnostic and Device Product Markets ... , At their most basic level, wellness ...
Cached Medicine News:Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 2Health News:Tom Daschle, Richard Gephardt and Other Health Care Leaders to Diagnose Health Care Reform Battle in the Final Days of the Debate 3Health News:FDA Takes Enforcement Action Against Ready-to-Eat Sandwich Manufacturer 2Health News:TPRF Gives US$25,000 to Help Provide Eye Care for Children in Palestinian Territories 2Health News:Vaccinating boys against human papillomavirus not cost-effective 2Health News:Vaccinating boys against human papillomavirus not cost-effective 3Health News:San Diego Hospice and The Institute for Palliative Medicine Program Wins National American Psychiatric Association Gold Achievement Award 2Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 2Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 3Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 4Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 5Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 6Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 7Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 8Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 9Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 10Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 11Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 12Health News:Reportlinker Adds The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets 13
Unipolar Atrial "J" Lead...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: